Skip To Main Content
Ivan Barilar on Muck Rack

Ivan Barilar

As seen in: Emerging Infectious Diseases, Nature, PLOS, Genome Medicine, The Lancet, medRxiv, European Respiratory Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ivan

Contact Ivan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Using genomic epidemiology and geographic activity spaces to investigate tuberculosis outbreaks in Botswana

|
By Chelsea Baker, Ivan Barilar, Daniel Parker, Kimberly M Fornace
| medRxiv
The authors have declared no competing interest. This work was supported by funding from the National Institute of Allergy and Infectious Diseases R01AI097045, R01AI147336, and R01AI170204. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Open in Who Shared View Duplicates (16) Issue with article?

Phylodynamic analysis reveals disparate transmission dynamics of Mycobacterium tuberculosis-complex lineages in Botswana

|
By Qiao Wang, Ivan Barilar, Volodymyr M. Minin, Chawangwa Modongo
| medRxiv
The authors have declared no competing interest. This study was funded by the US National Institute of Allergy and Infectious Diseases of the National Institutes of Health under grant R01AI147336 and R01AI097045 and the President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Open in Who Shared View Duplicates (12) Issue with article?

Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study

|
By Ivan Barilar, Experimental Mycobacteriology, Christian Utpatel, Tatiana Fernando
| The Lancet Verified
Summary In 2021, an estimated 4800 people developed rifampicin-resistant tuberculosis in Mozambique, 75% of which went undiagnosed. Detailed molecular data on rifampicin-resistant and multidrug-resistant (MDR) tuberculosis are not available. Here, we aimed at gaining precise data on the determinants of rifampicin-resistant and MDR tuberculosis in Mozambique.
Open in Who Shared Issue with article?
See all 11 articles